EPAS1 and paraganglioma: Previous studies reported that dysregulation and gain-of-function mutation of EPAS1 associated with neuroendocrine tumours such as paraganglioma and phaeochromocytomas by inducing pseudo-hypoxic tumour microenvironment [9,13,39].